{{Rsnum
|rsid=2407318
|Chromosome=16
|position=60413266
|Orientation=plus
|GMAF=0.2773
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 12.4 | 45.1 | 42.5
| HCB | 5.1 | 22.6 | 72.3
| JPT | 4.4 | 34.5 | 61.1
| YRI | 15.0 | 37.4 | 47.6
| ASW | 12.3 | 43.9 | 43.9
| CHB | 5.1 | 22.6 | 72.3
| CHD | 0.0 | 28.4 | 71.6
| GIH | 14.9 | 39.6 | 45.5
| LWK | 10.0 | 47.3 | 42.7
| MEX | 5.2 | 31.0 | 63.8
| MKK | 1.9 | 28.2 | 69.9
| TSI | 7.8 | 40.2 | 52.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2407318
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109425
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2407318
|overall_frequency_n=90
|overall_frequency_d=128
|overall_frequency=0.703125
|n_genomes=48
|n_genomes_annotated=0
|n_haplomes=73
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}